Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: A single-blind randomised placebo controlled trial

BMC Family Practice

Volumn 4, Issue , 2003, Pages 1-6

  Paile Hyvärinen, Maria ^a,b   Wahlbeck, Kristian ^b,c   Eriksson, Johan G ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; ORAL ANTIDIABETIC AGENT; PAROXETINE; SEX HORMONE BINDING GLOBULIN;

ADULT; ANOREXIA; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES CONTROL; DISEASE ASSOCIATION; FEMALE; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HAMILTON SCALE; HAND; HEADACHE; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN SENSITIVITY; MENTAL HEALTH; METABOLIC REGULATION; METABOLISM; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARESTHESIA; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING; TREATMENT OUTCOME;

EID: 2942752141     PISSN: 14712296     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2296-4-7     Document Type: Article

References (19)

1. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM and Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-94 Diabetes Care 1998, 21:518-524.
2. Nelson RG, Everhart JE, Knowler WC and Bennett PH: Incidence, prevalence, and risk factors for non-insulin dependent diabetes mellitus Primary Care 1988, 15:227-250.
3. Golay A, Felber JP, Dusmet M, Gomez F, Curchod B and Jequier E: Effect of weight loss on glucose disposal in obese and obese diabetic patients Int J Obes 1985, 9:181-190.
4. O'Kane M, Wiles PG and Wales JK: Fluoxetine in the treatment of obese type 2 diabetic patients Diabetic Med 1994, 11:105-110.
5. Gray DS, Fujioka K, Devine W and Bray GA: A randomized double-blind clinical trial of fluoxetine in obese diabetics Int J Obes Relat Metab Disord 1992, 16(Suppl 4):S67-S72.
6. Levine LR, Enas GG, Thompson WL, Byyny RL, Dauer AD, Kirby RW, Kreindler TG, Levy B, Lucas CP and McIlwain HH: Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study Int J Obes 1989, 13:635-645.
7. Maheux P, Ducros F, Bourque J, Garon J and Chiasson JL: Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss Int J Obes Relat Metab Disord 1997, 21:97-102.
8. Gavard JA, Lustman PJ and Clouse RE: Prevalence of depression in adults with diabetes: an epidemiological evaluation Diabetes Care 1993, 16:1167-1178.
9. Goodnick PJ, Kumar A, Henry JH, Buki VM and Goldberg RB: Sertraline in coexisting major depression and diabetes mellitus Psychopharmacol Bull 1997, 33:261-264.
10. Gjerris A, Bech P, Bojholm S and Rafaelsen OJ: The Hamilton Anxiety Scale J Affect Dis 1983, 5:163-170.
11. Montgomery SA and Asberg M: A new depression scale designed to be sensitive to change Brit J Psychiatry 1979, 134:322-389.
12. Beck AT, Ward CH, Mendelson M, Mock J and Erbaugh J: An inventory for measuring depression Arch Gen Psychiatry 1961, 4:561-571.
13. Hays RD, Sherbourne CD and Mazel R: The RAND 36-item Health Survey 1.0 Health Economics 1993, 2:217-277.
14. Eke T and Bates AK: Acute angle closure glaucoma associated with paroxetine BMJ 1997, 314(7091):1387.
15. Duncan D, Sayal K, McConnel H and Taylor D: Antidepressant interactions with warfarin Int Clin Psychopharmacology 1998, 13:87-94.
16. Meriläinen PT: Metabolic monitor Int J Clin Monit Comput 1987, 4:167-177.
17. Turner RC: The U.K. Prospective Diabetes Study. A review Diabetes Care 1998, 21(Suppl 4):C35-C38.
18. Abate N, Haffner SM, Garg A, Peshock RM and Grundy SM: Sex steroid hormones, upper body obesity, and insulin resistance J Clin Endocrinol Metab 2002, 10:4522-4527.
19. Cibula D, Skrha J, Hill M, Fanta M, Haakova L, VrbIkova J and Zivny J: Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome J Clin Endocrinol Metab 2002, 12:5821-5825.